We highlight some of the recent accomplishments in research and clinical trials by members of the department who apply nuclear medicine to diagnose and treat illnesses including cancer.
The Bay Area Community Of Bay area RAdionuclide imagers (COBRA) meeting returned this year and was hosted at UC Davis on May 25, 2022. COBRA, originally conceived in 2006 by the late Bruce Hasegawa, PhD - brilliant investigator, educator and mentor at UCSF – and Ling Shao.
Submitted by cnicholson on September 16, 2020 - 9:58am
Because treatment for prostate cancer is highly individualized, molecular imaging technologies are helping to improve the ways in which prostate cancer is diagnosed and treated.
Submitted by cnicholson on August 6, 2019 - 6:22am
Recently, scientists from the UC San Francisco Departments of Radiology and Biomedical Imaging, Urology and Radiation Oncology came together to study the impact of 68Ga-PSMA-11 PET on post radical prostatectomy (RP) salvage radiotherapy.
The UC San Francisco Department of Radiology and Biomedical Imaging had a strong presence at the recent Society for Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting held June 22-25, 2019 in Anaheim, CA.
Scientists at UCSF and UCLA designed a single-arm prospective trial on 635 patients with biochemically recurrent prostate cancer to assess the accuracy of 68Ga-PSMA-11 PET.
Submitted by cnicholson on December 20, 2018 - 7:04am
Scientists at UC San Francisco have just conducted the first-in-human Phase I study of CTT1057 in patients with localized and metastatic prostate cancer.
UCSF Imaging’s Miguel Hernandez Pampaloni, MD, recently authored a study on PET imaging using regadenoson as a stressor to measure reduced myocardal and coronary blood flow for patients after orthotopic heart transplants.
